Edwards Lifesciences Corporation $EW Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 14.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,642,618 shares of the medical research company’s stock after selling 604,346 shares during the period. Nordea Investment Management AB owned about 0.63% of Edwards Lifesciences worth $312,646,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Hilltop National Bank grew its holdings in Edwards Lifesciences by 7.2% during the fourth quarter. Hilltop National Bank now owns 9,200 shares of the medical research company’s stock worth $784,000 after acquiring an additional 620 shares during the period. Sagespring Wealth Partners LLC lifted its holdings in Edwards Lifesciences by 2.4% in the fourth quarter. Sagespring Wealth Partners LLC now owns 10,572 shares of the medical research company’s stock valued at $901,000 after acquiring an additional 245 shares during the period. Everhart Financial Group Inc. boosted its position in shares of Edwards Lifesciences by 8.4% during the 4th quarter. Everhart Financial Group Inc. now owns 6,159 shares of the medical research company’s stock worth $525,000 after purchasing an additional 475 shares in the last quarter. Central Pacific Bank Trust Division acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth $775,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth $34,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on EW shares. Evercore reaffirmed an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a research note on Monday, January 12th. The Goldman Sachs Group restated a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,827,387.38. This represents a 34.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 61,718 shares of company stock valued at $5,236,281. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE:EW opened at $82.52 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The firm has a market cap of $47.92 billion, a price-to-earnings ratio of 45.09, a PEG ratio of 2.15 and a beta of 0.93. The stock’s 50-day moving average price is $82.23 and its two-hundred day moving average price is $81.64. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.